Results 321 to 330 of about 7,977,848 (398)

Reconciling devolution with health financing and public financial management: challenges and policy options for the health sector. [PDF]

BMJ Glob Health
Ravishankar N, Mathauer I, Barroy H, Vîlcu I, Chaitkin M, Offosse MJ, Co PA, Nakyanzi A, Mbuthia B, Lourenço S, Mardani H, Kutzin J.   +11 more
europepmc   +1 more source

Governance Challenges in International Health Financing and Implications for the New Pandemic Fund

, 2023
Brown GW, Rhodes N, Tacheva B, Loewenson R, Shahid M, Poitier F.   +5 more
europepmc   +1 more source

Health financing policies during the COVID-19 pandemic and implications for universal health care: a case study of 15 countries.

Lancet Glob Health, 2023
De Foo C, Verma M, Tan SY, Hamer J, van der Mark N, Pholpark A, Hanvoravongchai P, Cheh PLJ, Marthias T, Mahendradhata Y, Putri LP, Hafidz F, Giang KB, Khuc THH, Van Minh H, Wu S, Caamal-Olvera CG, Orive G, Wang H, Nachuk S, Lim J, de Oliveira Cruz V, Yates R, Legido-Quigley H.   +23 more
europepmc   +1 more source

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

Molecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul, François Guillonneau, Odile Blanchet, Hamza Lasla, Audrey Rousseau, Catherine Guette, Alice Boissard, Cécile Henry, Morgan Dhondt, Pascal Jézéquel, Philippe Menei, Jean‐Michel Lemée   +11 more
wiley   +1 more source

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

Molecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef, Hana Barhom, Sumit Chatterji, Netta Hecht, Oran Warhaftig, Iris Kamer, Oranit Zadok, Jair Bar, Limor Broday, Amir Onn, Michael Peled   +10 more
wiley   +1 more source

Private finance scheme for Worcester. Journal has not presented balanced picture of modern health planning.

, 2000
Brian McCloskey
openalex  

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Forecasting health financing sustainability under the unified pool reform: evidence from China's Urban Employee Basic Medical Insurance. [PDF]

Health Econ Rev
Wu J, Yang H, Pan X.
europepmc   +1 more source

PHP24 ANALYSIS OF “INNOVATOR” DRUGS FINANCED BY SPANISH NATIONAL HEALTH SERVICE OVER THE PERIOD 1996-2003

, 2004
MD Gaspar, P Modamio, CF Lastra, E. De Marino   +3 more
openalex   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source